Skip to main content
SpringerLink
Log in

DIABETES

Long-term follow-up of intensive glycaemic control in type 2 diabetes

  • News & Views
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

In a 15-year follow-up of the VADT study, no differences in major cardiovascular outcomes were found among individuals with type 2 diabetes mellitus who underwent either intensive or standard glucose control. These results indicate that intensification of glycaemic control might not be expected to mitigate the risk of cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Clinical trials on intensive versus standard glycaemic control.

References

  1. Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).

    Article  Google Scholar 

  2. Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).

    Article  CAS  Google Scholar 

  3. Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).

    Article  CAS  Google Scholar 

  4. Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).

    Article  CAS  Google Scholar 

  5. Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).

    Article  CAS  Google Scholar 

  6. Hayward, R. A. et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372, 2197–2206 (2015).

    Article  CAS  Google Scholar 

  7. Zoungas, S. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392–1406 (2014).

    Article  Google Scholar 

  8. Reaven, P. D. et al. Intensive glucose control in patients with type 2 diabetes − 15-year follow-up. N. Engl. J. Med. 380, 2215–2224 (2019).

    Article  CAS  Google Scholar 

  9. Patel, K. V., de Albuquerque Rocha, N. & McGuire, D. K. Diabetes medications and cardiovascular outcome trials: lessons learned. Cleve. Clin. J. Med. 84, 759–767 (2017).

    Article  Google Scholar 

  10. Das, S. R. et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J. Am. Coll. Cardiol. 72, 3200–3223 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Kershaw V. Patel & Darren K. McGuire

Authors
  1. Kershaw V. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Darren K. McGuire
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darren K. McGuire.

Ethics declarations

Competing interests

D.K.M. reports honoraria for trial leadership from AstraZeneca, Boehringer Ingelheim, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Lilly US, Merck & Co, Novo Nordisk, Pfizer and Sanofi Aventis; and honoraria for consulting for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Lilly US, Merck & Co, Metavant, Novo Nordisk, Pfizer and Sanofi Aventis. K.V.P declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, K.V., McGuire, D.K. Long-term follow-up of intensive glycaemic control in type 2 diabetes. Nat Rev Cardiol 16, 517–518 (2019). https://doi.org/10.1038/s41569-019-0241-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-019-0241-y

  • Springer Nature Limited

This article is cited by

Search

Navigation